Ascentage Pharma secures major platform at ASCO 2026. The biopharmaceutical company has earned six abstract selections for the American Society of Clinical Oncology Annual Meeting, including three rapid oral presentations highlighting clinical trial data from key oncology candidates. Olverembatinib, Lisaftoclax, and Alrizomadlin represent the company's pipeline focused on addressing unmet cancer treatment needs. This marks Ascentage's ninth consecutive year presenting at ASCO, underscoring sustained recognition from the global scientific community. The presentations will showcase the company's R&D capabilities and clinical progress across multiple studies, potentially influencing investor sentiment and market positioning in the competitive biopharmaceutical sector.
Post from MarketNews_en
Log in to interact with content.